Kansas sues Pfizer, $PFE, over 'misrepresentations' and 'adverse affects' of COVID-19 vaccine

The U.S. state of Kansas sued Pfizer on Monday, accusing the company of misleading the public about its COVID-19 vaccine by hiding risks and making false claims about its effectiveness.

In a lawsuit filed in the District Court of Thomas County, the state alleged that the New York-based drugmaker's false statements violated the Kansas Consumer Protection Act. Kansas is seeking unspecified monetary damages.

"Pfizer made multiple misleading statements to deceive the public about its vaccine at a time when Americans needed the truth," said Kansas Attorney General Kris Kobach, a Republican, in a statement.

The lawsuit claims that, beginning shortly after the vaccine's rollout in early 2021, Pfizer concealed evidence that the shot was linked to pregnancy complications, including miscarriage, as well as inflammation in and around the heart, known as myocarditis and pericarditis.

"The representations made by Pfizer about its COVID-19 vaccine have been accurate and science-based," Pfizer said in a statement, adding that it believes the lawsuit has no merit.

The U.S. Food and Drug Administration added a warning about myocarditis and pericarditis to the vaccine's label in June 2021. These side effects are rare and most often occur in adolescent boys and young men.

A 2023 review of 21 studies by the U.S. National Institutes of Health concluded that COVID vaccines were not linked to miscarriage.

Kansas also accused Pfizer of falsely claiming that its vaccine, which was developed with German partner BioNTech for the original strain of the virus, retained high effectiveness against mutated variants and would prevent not only illness but also transmission.

Texas Attorney General Ken Paxton filed a similar lawsuit against Pfizer last year, which remains pending. Pfizer has also called that case meritless.

Kobach said on Monday that other states had been collaborating with Kansas in its investigation and are expected to file lawsuits as well.

BioNTech is not a defendant in the case.

Unusual Whales does not confirm the information's truthfulness or accuracy of the associated references, data, and cannot verify any of the information. Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Options, investing, trading is risky, and losses are more expected than profits. Please do own research before investing. Please only subscribe after reading our full terms and understanding options and the market, and the inherent risks of trading. It is highly recommended not to trade on this, or any, information from Unusual Whales. Markets are risky, and you will likely lose some or all of your capital. Please check our terms for full details.
Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Certain investment planning tools available on Unusual Whales may provide general investment education based on your input. You are solely responsible for determining whether any investment, investment strategy, security or related transaction is appropriate for you based on your personal investment objectives, financial circumstances and risk tolerance. You should consult your legal or tax professional regarding your specific situation. See terms for more information.